Antiglucocorticoids, neurogenesis and depression

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 249-264

  Fitzsimons, Carlos P ^a   van Hooijdonk, Lenneke W A ^a   Morrow, John A ^a   Peeters, Bernard W M M ^c   Hamilton, Niall ^b   Craighead, Mark ^b   Vreugdenhil, Erno ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NV ORGANON   (Netherlands)

Author keywords

Anti glucocorticoids; Antidepressants; Dentate gyrus; Depression; Doublecortin like kinase; Glucocorticoid receptor; Hippocampus; Neurogenesis; Stress

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 6 AMINOPYRIMIDINEDIONE DERIVATIVE; A 348441; ALPHA METHYLTRYPTAMINE SULFONAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; ARYLSULFONAMIDE DERIVATIVE; AZADECALIN DERIVATIVE; CP 394531; CP 409069; CYPROTERONE ACETATE; DEXAMETHASONE; DIHYDROQUINOLINE DERIVATIVE; DOUBLECORTIN; FLUOXETINE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MIFEPRISTONE; MONOAMINE OXIDASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PREDNISONE; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE; TRIFLUOROMETHYL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; GLUCOCORTICOID;

ANOREXIA; APOPTOSIS; CENTRAL NERVOUS SYSTEM; CHRONIC STRESS; CLINICAL TRIAL; COGNITIVE DEFECT; CUSHING DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; ENDOMETRIUM HYPERPLASIA; FATIGUE; GENETIC PREDISPOSITION; HIPPOCAMPUS; HOT FLUSH; HUMAN; HYPOMANIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSOMNIA; MAJOR DEPRESSION; MENTAL STRESS; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PATHOGENESIS; PSYCHOPATHY; PSYCHOSIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREMOR; VOMITING; WEIGHT GAIN; ANIMAL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; GROWTH, DEVELOPMENT AND AGING; METABOLISM; NERVOUS TISSUE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MODELS, MOLECULAR; NERVE TISSUE; RECEPTORS, GLUCOCORTICOID; STRESS, PSYCHOLOGICAL;

EID: 65449143589     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787316001     Document Type: Review

References (229)

1. de Kloet, E.R.; Joels, M.; Holsboer, F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci., 2005, 6, 463-75.
2. De Kloet, E.R.; Vreugdenhil, E.; Oitzl, M.S.; Joels, M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev., 1998, 19, 269-301.
3. Nemeroff, C.B. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry, 1996, 1, 336-42.
4. McEwen, B.S.; de Kloet, E.R.; Rostene, W. Adrenal steroid receptors and actions in the nervous system. Physiol. Rev., 1986, 66, 1121-88.
5. Reul, J.M.; de Kloet, E.R. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology, 1985, 117, 2505-11.
6. de Kloet, E.R.; Reul, J.M. Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology, 1987, 12, 83-105.
7. Reul, J.M.; Gesing, A.; Droste, S.; Stec, I.S.; Weber, A.; Bachmann, C.; Bilang-Bleuel, A.; Holsboer, F.; Linthorst, A.C. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur. J. Pharmacol., 2000, 405, 235-49.
8. Dallman, M.F.; Akana, S.F.; Jacobson, L.; Levin, N.; Cascio, C.S.; Shinsako, J. Characterization of corticosterone feedback regulation of ACTH secretion. Ann. N. Y. Acad. Sci., 1987, 512, 402-14.
9. de Kloet, E.R.; McEwen, B.S. Differences between cytosol receptor complexes with corticosterone and dexamethasone in hippocampal tissue from rat brain. Biochim. Biophys. Acta, 1976, 421, 124-32.
10. Fuxe, K.; Wikstrom, A.C.; Okret, S.; Agnati, L.F.; Harfstrand, A.; Yu, Z.Y.; Granholm, L.; Zoli, M.; Vale, W.; Gustafsson, J.A. Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinology, 1985, 117, 1803-12.
11. Gerlach, J.L.; McEwen, B.S. Rat brain binds adrenal steroid hormone: radioautography of hippocampus with corticosterone. Science, 1972, 175, 1133-36.
12. Han, F.; Ozawa, H.; Matsuda, K.; Nishi, M.; Kawata, M. Colocalization of mineralocorticoid receptor and glucocorticoid receptor in the hippocampus and hypothalamus. Neurosci. Res., 2005, 51, 371-81.
13. Herman, J.P.; Patel, P.D.; Akil, H.; Watson, S.J. Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat. Mol. Endocrinol., 1989, 3, 1886-94.
14. Reul, J.M.; de Kloet, E.R. Anatomical resolution of two types of corticosterone receptor sites in rat brain with in vitro autoradiography and computerized image analysis. J. Steroid Biochem., 1986, 24, 269-72.
15. Reul, J.M.; de Kloet, E.R.; van Sluijs, F.J.; Rijnberk, A.; Rothuizen, J. Binding characteristics of mineralocorticoid and glucocorticoid receptors in dog brain and pituitary. Endocrinology, 1990, 127, 907-15.
16. Van Eekelen, J.A.; Jiang, W.; de Kloet, E.R.; Bohn, M.C. Distribution of the mineralocorticoid and the glucocorticoid receptor mRNAs in the rat hippocampus. J. Neurosci. Res., 1988, 21, 88-94.
17. Herman, J.P.; Cullinan, W.E. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci., 1997, 20, 78-84.
18. Joels, M. Role of corticosteroid hormones in the dentate gyrus. Prog. Brain Res., 2007, 163, 355-70.
19. Joels, M.; Karst, H.; Alfarez, D.; Heine, V.M.; Qin, Y.; van, R.E.; Verkuyl, M.; Lucassen, P.J.; Krugers, H.J. Effects of chronic stress on structure and cell function in rat hippocampus and hypothalamus. Stress, 2004, 7, 221-31.
20. Vreugdenhil, E.; de Kloet, E.R.; Schaaf, M.; Datson, N.A. Genetic dissection of corticosterone receptor function in the rat hippocampus. Eur. Neuropsychopharmacol., 2001, 11, 423-30.
21. Holsboer, F.; Barden, N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev., 1996, 17, 187-205.
22. McEwen, B.S. Stress and hippocampal plasticity. Annu. Rev. Neurosci., 1999, 22, 105-22.
23. McEwen, B.S.; Sapolsky, R.M. Stress and cognitive function. Curr. Opin. Neurobiol., 1995, 5, 205-16.
24. Carroll, B.J.; Martin, F.I.; Davies, B. Pituitary-adrenal function in depression. Lancet, 1968, 1, 1373-74.
25. Sapolsky, R.M. Stress hormones: good and bad. Neurobiol. Dis., 2000, 7, 540-42.
26. Lowy, M.T.; Reder, A.T.; Gormley, G.J.; Meltzer, H.Y. Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biol. Psychiatry, 1988, 24, 619-30.
27. Miller, K.B.; Nelson, J.C. Does the dexamethasone suppression test relate to subtypes, factors, symptoms, or severity? Arch. Gen. Psychiatry, 1987, 44, 769-74.
28. Wodarz, N.; Rupprecht, R.; Kornhuber, J.; Schmitz, B.; Wild, K.; Braner, H.U.; Riederer, P. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. J. Affect. Disord., 1991, 22, 241-48.
29. Caspi, A.; Sugden, K.; Moffitt, T.E.; Taylor, A.; Craig, I.W.; Harrington, H.; McClay, J.; Mill, J.; Martin, J.; Braithwaite, A. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 2003, 301, 386-89.
30. Fava, M.; Kendler, K.S. Major depressive disorder. Neuron, 2000, 28, 335-41.
31. Gold, P.W.; Chrousos, G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry, 2002, 7, 254-75.
32. Nestler, E.J.; Gould, E.; Manji, H.; Buncan, M.; Duman, R.S.; Greshenfeld, H.K.; Hen, R.; Koester, S.; Lederhendler, I.; Meaney, M. et al. Preclinical models: status of basic research in depression. Biol. Psychiatry, 2002, 52, 503-28.
33. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Koretz, D.; Merikangas, K.R.; Rush, A.J.; Walters, E.E.; Wang, P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289, 3095-105.
34. Ansell, B.M. Psyche and rheuma. J. Int. Med. Res., 1976, 4, 50-53.
35. Wolkowitz, O.M. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology, 1994, 19, 233-55.
36. Strekalova, T.; Spanagel, R.; Bartsch, D.; Henn, F.A.; Gass, P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology, 2004, 29, 2007-17.
37. Willner, P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl.), 1997, 134, 319-29.
38. Willner, P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology, 2005, 52, 90-110.
39. Karten, Y.J.; Nair, S.M.; van, E.L.; Sibug, R.; Joels, M. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. Proc. Natl. Acad. Sci. USA, 1999, 96, 13456-61.
40. Modell, S.; Lauer, C.J.; Schreiber, W.; Huber, J.; Krieg, J.C.; Holsboer, F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology, 1998, 18, 253-62.
41. DeBattista, C.; Belanoff, J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol. Metab., 2006, 17, 117-21.
42. Keller, J.; Flores, B.; Gomez, R.G.; Solvason, H.B.; Kenna, H.; Williams, G.H.; Schatzberg, A.F. Cortisol circadian rhythm alterations in psychotic major depression. Biol. Psychiatry, 2006, 60, 275-81.
43. Jeffcoate, W.J.; Silverstone, J.T.; Edwards, C.R.; Besser, G.M. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q. J. Med., 1979, 48, 465-72.
44. Linkowski, P. Circadian rhythm in depressive disorders. Arch. Belg., 1986, 44, 353-56.
45. Sachar, E.J.; Hellman, L.; Roffwarg, H.P.; Halpern, F.S.; Fukushima, D.K.; Gallagher, T.F. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch. Gen. Psychiatry, 1973, 28, 19-24.
46. Mortola, J.F.; Liu, J.H.; Gillin, J.C.; Rasmussen, D.D.; Yen, S.S. Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J. Clin. Endocrinol. Metab., 1987, 65, 962-68.
47. Bachmann, C.G.; Linthorst, A.C.; Holsboer, F.; Reul, J.M. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology, 2003, 28, 1056-67.
48. Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23, 477-501.
49. Pariante, C.M. Glucocorticoid receptor function in vitro in patients with major depression. Stress, 2004, 7, 209-19.
50. Reus, V.I.; Wolkowitz, O.M. Antiglucocorticoid drugs in the treatment of depression. Expert. Opin. Investig. Drugs, 2001, 10, 1789-96.
51. Swaab, D.F.; Bao, A.M.; Lucassen, P.J. The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev., 2005, 4, 141-94.
52. Pariante, C.M.; Miller, A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry, 2001, 49, 391-404.
53. Lu, X.; Sharkey, L.; Bartfai, T. The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol. Disord. Drug Targets, 2007, 6, 183-92.
54. Tortorella, C.; Neri, G.; Nussdorfer, G.G. Galanin in the regulation of the hypothalamic-pituitary-adrenal axis (Review). Int. J. Mol. Med., 2007, 19, 639-47.
55. Marco, E.J.; Wolkowitz, O.M.; Vinogradov, S.; Poole, J.H.; Lichtmacher, J.; Reus, V.I. Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study. World J. Biol. Psychiatry, 2002, 3, 156-61.
56. Murphy, B.E. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology, 1997, 22(Suppl. 1), S125-S32.
57. Wolkowitz, O.M.; Reus, V.I. Treatment of depression with antiglucocorticoid drugs. Psychosom. Med., 1999, 61, 698-711.
58. Wolkowitz, O.M.; Reus, V.I.; Chan, T.; Manfredi, F.; Raum, W.; Johnson, R.; Canick, J. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol. Psychiatry, 1999, 45, 1070-74.
59. Wolkowitz, O.M.; Reus, V.I.; Manfredi, F.; Ingbar, J.; Brizendine, L.; Weingartner, H. Ketoconazole administration in hypercortisolemic depression. Am. J. Psychiatry, 1993, 150, 810-12.
60. Jahn, H.; Schick, M.; Kiefer, F.; Kellner, M.; Yassouridis, A.; Wiedemann, K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch. Gen. Psychiatry, 2004, 61, 1235-44.
61. Holsboer, F. High-quality antidepressant discovery by understanding stress hormone physiology. Ann. N. Y. Acad. Sci., 2003, 1007, 394-404.
62. Belanoff, J.K.; Flores, B.H.; Kalezhan, M.; Sund, B.; Schatzberg, A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol., 2001, 21, 516-21.
63. Murphy, B.E.; Filipini, D.; Ghadirian, A.M. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J. Psychiatry Neurosci., 1993, 18, 209-13.
64. Reus, V.I.; Wolkowitz, O.M. Antiglucocorticoid drugs in the treatment of depression. Expert. Opin. Investig. Drugs, 2001, 10, 1789-96.
65. Belanoff, J.K.; Rothschild, A.J.; Cassidy, F.; DeBattista, C.; Baulieu, E.E.; Schold, C.; Schatzberg, A.F. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry, 2002, 52, 386-92.
66. Flores, B.H.; Kenna, H.; Keller, J.; Solvason, H.B.; Schatzberg, A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology, 2006, 31, 628-36.
67. Simpson, G.M.; El, S.A.; Loza, N.; Kingsbury, S.J.; Fayek, M.; Rady, A.; Fawzy, W. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J. Clin. Psychiatry, 2005, 66, 598-602.
68. Sartor, O.; Cutler, G.B., Jr. Mifepristone: treatment of Cushing's syndrome. Clin. Obstet. Gynecol., 1996, 39, 506-10.
69. van der Lely, A.J.; Foeken, K.; van der Mast, R.C.; Lamberts, S.W. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann. Intern. Med., 1991, 114, 143-44.
70. Sapolsky, R. Taming stress. Sci. Am., 2003, 289, 86-95.
71. Nieman, L.K.; Chrousos, G.P.; Kellner, C.; Spitz, I.M.; Nisula, B.C.; Cutler, G.B.; Merriam, G.R.; Bardin, C.W.; Loriaux, D.L. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab., 1985, 61, 536-40.
72. Lamberts, S.W.; Koper, J.W.; de Jong, F.H. The endocrine effects of long-term treatment with mifepristone (RU 486). J. Clin. Endocrinol. Metab., 1991, 73, 187-91.
73. Sonino, N. The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med., 1987, 317, 812-18.
74. Carroll, B.J.; Rubin, R.T. Is mifepristone useful in psychotic depression? Neuropsychopharmacology, 2006, 31, 2793-94.
75. DeBattista, C.; Belanoff, J.; Glass, S.; Khan, A.; Horne, R.L.; Blasey, C.; Carpenter, L.L.; Alva, G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry, 2006, 60, 1343-49.
76. Neubig, R.R.; Spedding, M.; Kenakin, T.; Christopoulos, A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev, 2003, 55, 597-606.
77. Miner, J.N.; Hong, M.H.; Negro-Vilar, A. New and improved glucocorticoid receptor ligands. Expert Opin. Investig. Drugs, 2005, 14, 1527-45.
78. Nihalani, N.D.; Schwartz, T.L. Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Curr. Opin. Investig. Drugs, 2007, 8, 563-69.
79. Backes, B.J.; Hamilton, G.L.; Nguyen, P.; Wilcox, D.; Fung, S.; Wang, J.; Grynfarb, M.; Goos-Nilsson, A.; Jacobson, P.B.; von Geldern, T.W. Parallel strategies for the preparation and selection of liver-targeted glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 40-44.
80. Richards, S.J.; von Geldern, T.W.; Jacobson, P.; Wilcox, D.; Nguyen, P.; Ohman, L.; Osterlund, M.; Gelius, B.; Grynfarb, M.; Goos-Nilsson, A.; Wang, J.; Fung, S.; Kalmanovich, M. Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 6086-90.
81. Honer, C.; Nam, K.; Fink, C.; Marshall, P.; Ksander, G.; Chatelain, R.E.; Cornell, W.; Steele, R.; Schweitzer, R.; Schumacher, C. Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol. Pharmacol., 2003, 63, 1012-20.
82. Bothe, U.; Schubert, G.; Kaufmann, G.; Sobek, L.; Patchev, V.; Hillisch, A.: 11 substituted steroids as glucocorticoid receptor antagonists and their application. In: DE: Jenapharm GmbH & Co. KG, Germany; 2004: 10.
83. Jiang, W.; Fiordeliso, J.J.; Allan, G.; Linton, O.; Tannenbaum, P.; Xu, J.; Zhu, P.; Gunnet, J.; Demarest, K.; Lundeen, S.; Sui, Z. Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Bioorg. Med. Chem. Lett., 2007, 17, 1471-74.
84. Ring, S.; Schubert, G.; Sobek, L.: Preparation of 11-benzaldoxime derivatives of D-homoestra-4,9-dien-3-ones as antiglucocorticoids. In: WO: Bayer Schering, Pharma A.-G.; 2007: p. 35.
85. Mohler, M.L.; He, Y.; Wu, Z.; Hong, S.S.; Miller, D.D. Nonsteroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy. Expert Opin. Ther. Pat., 2007, 17, 59-81.
86. Clark, R.D.; Ray, N.C.; Blaney, P.; Crackett, P.H.; Hurley, C.; Williams, K.; Dyke, H.J.; Clark, D.E.; Lockey, P.M.; Devos, R. et al. 2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 5704-08.
87. Clark, R.D.; Ray, N.C.; Blaney, P.; Hurley, C.; Williams, K.; Hunt, H.; Clark, D.: Preparation of azadecalin derivatives as glucocorticoid receptor modulators. In: WO: Corcept Therapeutics, Inc.; 2005, p. 105.
88. Clark, R.D.; Ray, N.C.; Blaney, P.M.; Hurley, C.A.; Williams, K.: Fused ring azadecalin glucocorticoid receptor modulators. In: WO: Corcept Therapeutics, Inc.; 2005, p. 160.
89. Clark, R.D.; Ray, N.C.; Williams, K.; Crackett, P.H.; Hickin, G.; Clark, D.A.: Preparation of pyrimidinediones as glucocorticoid receptor modulators. In. US: Corcept Therapeutics, Inc.; 2006, p. 38.
90. Ray, N.C.; Clark, R.D.; Clark, D.E.; Williams, K.; Hickin, H.G.; Crackett, P.H.; Dyke, H.J.; Lockey, P.M.; Wong, M.; Devos, R. et al. Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. Bioorg. Med. Chem. Lett., 2007, 17, 4901-05.
91. Hamilton, N.M.; Grove, S.J.A.; Kiczun, M.J.; Morphy, J.R.; Sherborne, B.; Littlewood, P.T.A.; Brown, A.R.; Kingsbury, C.; Ohlmeyer, M.; Ho, K.K. Compounds with medicinal effects due to interaction with the glucocorticoid receptor. In: WO: Organon, N.V. Pharmacopeia Drug Discovery, Inc. 2007, p. 52.
92. Marshall, D.R.; Rodriguez, G.; Thomson, D.S.; Nelson, R.; Capolina, A. Alpha-methyltryptamine sulfonamide derivatives as novel glucocorticoid receptor ligands. Bioorg. Med. Chem. Lett., 2007, 17, 315-19.
93. Takahashi, H.; Bekkali, Y.; Capolino, A.J.; Gilmore, T.; Goldrick, S.E.; Nelson, R.M.; Terenzio, D.; Wang, J.; Zuvela-Jelaska, L.; Proudfoot, J.; Nabozny, G.; Thomson, D. Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands. Bioorg. Med. Chem. Lett., 2006, 16, 1549-52.
94. Betageri, R.; Zhang, Y.; Zindell, R.M.; Kuzmich, D.; Kirrane, T.M.; Bentzien, J.; Cardozo, M.; Capolino, A.J.; Fadra, T.N.; Nelson, R.M.; Paw, Z.; Shih, D.T.; Shih, C.K.; Zwela-Jelaska, L.; Nabozny, G.; Thomson, D.S. Trifluoromethyl group as a pharmacophore: effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. Bioorg. Med. Chem. Lett., 2005, 15, 4761-69.
95. Barker, M.; Clackers, M.; Copley, R.; Demaine, D.A.; Humphreys, D.; Inglis, G.G.; Johnston, M.J.; Jones, H.T.; Haase, M.V.; House, D.; Loiseau, R.; Nisbet, L.; Pacquet, F.; Skone, P.A.; Shanahan, S.E.; Tape, D.; Vinader, V.M.; Washington M.; Uniqs, I.; Upton, R.; McLay, I.M.; Macdonald, S.J. Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J. Med. Chem., 2006, 49, 4216-31.
96. Barker, M.; Clackers, M.; Demaine, D.A.; Humphreys, D.; Johnston, M.J.; Jones, H.T.; Pacquet, F.; Pritchard, J.M.; Salter, M.; Shanahan, S.E.; Skone, P.A.; Vinader, V.M.; Uings, I.; McLay, I.M.; Macdonald, S.J. Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method. J. Med. Chem., 2005, 48, 4507-10.
97. Morgan, B.P.; Swick, A.G.; Hargrove, D.M.; LaFlamme, J.A.; Moynihan, M.S.; Carroll, R.S.; Martin, K.A.; Lee, E.; Decosta, D.; Bordner, J. Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J. Med. Chem., 2002, 45, 2417-24.
98. Einstein, M.; Greenlee, M.; Rouen, G.; Sitlani, A.; Santoro, J.; Wang, C.; Pandit, S.; Mazur, P.; Smalera, I.; Weaver, A.P. et al. Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism. J. Steroid. Biochem. Mol Biol, 2004, 92, 345-56.
99. Link, J.T.; Sorensen, B.; Patel, J.; Grynfarb, M.; Goos-Nilsson, A.; Wang, J.; Fung, S.; Wilcox, D.; Zinker, B.; Nguyen, P. et al. Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators. J. Med. Chem., 2005, 48, 5295-304.
100. Neigh, G.N.; Nemeroff, C.B. Reduced glucocorticoid receptors: consequence or cause of depression? Trends Endocrinol. Metab., 2006, 17, 124-25.
101. Young, A.H. Antiglucocoticoid treatments for depression. Aust. N. Z. J. Psychiatry, 2006, 40, 402-05.
102. Cink, R.D.; Zou, D.; Leanna, M.R.; Toma, P.H.; Long, M.A.: Improved crystalline form of A-348441. In: WO: Karo Bio AB, Swed; 2007: p. 25.
103. Wuest, F.; Kniess, T.; Bergmann, R.; Henry, B.; Pietzsch, J. Synthesis and radiopharmacological characterization of 11CAL-438 as a nonsteroidal ligand for imaging brain glucocorticoid receptors. Bioorg. Med. Chem. Lett., 2007, 17, 4035-39.
104. Wust, F.; Carlson, K.E.; Katzenellenbogen, J.A. Synthesis of novel arylpyrazolo corticosteroids as potential ligands for imaging brain glucocorticoid receptors. Steroids, 2003, 68, 177-91.
105. Wust, F.; Kniess, T.; Kretzschmar, M.; Bergmann, R. Synthesis and radiopharmacological evaluation of 2′-(4-fluorophenyl)-21- 18Ffluoro-20-oxo-11beta,17alpha-dihydroxy-pregn-4-eno3, 2-cpyrazole as potential glucocorticoid receptor ligand for positron emission tomography (PET). Bioorg. Med. Chem. Lett., 2005, 15, 1303-06.
106. Simons, S.S., Jr. How much is enough? Modulation of dose-response curve for steroid receptor-regulated gene expression by changing concentrations of transcription factor. Curr. Top. Med. Chem., 2006, 6, 271-85.
107. Zhou, J.; Cidlowski, J.A. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids, 2005, 70, 407-17.
108. Thomson, F.B., C.; Craighead, M.; Eason, S.; Hillier, A.; Peeters, B.; Speake, M.; and Watson, L. In vivo and in vitro characterisation of the glucocorticoid receptor antagonist Org 34517. J. Affect. Dis., 2004, 78, S99-S142.
109. Zhang, S.; Jonklaas, J.; Danielsen, M. The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids, 2007, 72, 600-08.
110. Hittelman, A.B.; Burakov, D.; Iniguez-Lluhi, J.A.; Freedman, L.P.; Garabedian, M.J. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J., 1999, 18, 5380-88.
111. Luisi, B.F.; Xu, W.X.; Otwinowski, Z.; Freedman, L.P.; Yamamoto, K.R.; Sigler, P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature, 1991, 352, 497-505.
112. Hard, T.; Kellenbach, E.; Boelens, R.; Kaptein, R.; Dahlman, K.; Carlstedt-Duke, J.; Freedman, L.P.; Maler, B.A.; Hyde, E.I.; Gustafsson, J.A. 1H NMR studies of the glucocorticoid receptor DNA-binding domain: sequential assignments and identification of secondary structure elements. Biochemistry, 1990, 29, 9015-23.
113. Hard, T.; Kellenbach, E.; Boelens, R.; Maler, B.A.; Dahlman, K.; Freedman, L.P.; Carlstedt-Duke, J.; Yamamoto, K.R.; Gustafsson, J.A.; Kaptein, R. Solution structure of the glucocorticoid receptor DNA-binding domain. Science, 1990, 249, 157-60.
114. Bledsoe, R.K.; Montana, V.G.; Stanley, T.B.; Delves, C.J.; Apolito, C.J.; McKee, D.D.; Consler, T.G.; Parks, D.J.; Stewart, E.L.; Willson, T.M.; Lambert, H.M.; Moore, J.T.; Pearce, K.H.; Xu, H.E. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell, 2002, 110, 93-105.
115. Kauppi, B.; Jakob, C.; Farnegardh, M.; Yang, J.; Ahola, H.; Alarcon, M.; Calles, K.; Engstrom, O.; Harlan, J.; Muchmore, S. et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem., 2003, 278, 22748-54.
116. Williams, S.P.; Sigler, P.B. Atomic structure of progesterone complexed with its receptor. Nature, 1998, 393, 392-96.
117. Brzozowski, A.M.; Pike, A.C.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753-58.
118. Pike, A.C.; Brzozowski, A.M.; Hubbard, R.E.; Bonn, T.; Thorsell, A.G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J.A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J., 1999, 18, 4608-18.
119. Sack, J.S.; Kish, K.F.; Wang, C.; Attar, R.M.; Kiefer, S.E.; An, Y.; Wu, G.Y.; Scheffler, J.E.; Salvati, M.E.; Krystek, S.R., Jr. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. USA, 2001, 98, 4904-09.
120. Li, Y.; Suino, K.; Daugherty, J.; Xu, H.E. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol. Cell, 2005, 19, 367-80.
121. Bledsoe, R.K.; Stewart, E.L.; Pearce, K.H. Structure and function of the glucocorticoid receptor ligand binding domain. Vitam. Horm., 2004, 68, 49-91.
122. Steinmetz, A.C.; Renaud, J.P.; Moras, D. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct., 2001, 30, 329-59.
123. Shiau, A.K.; Barstad, D.; Loria, P.M.; Cheng, L.; Kushner, P.J.; Agard, D.A.; Greene, G.L. The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 1998, 95, 927-37.
124. Shiau, A.K.; Barstad, D.; Radek, J.T.; Meyers, M.J.; Nettles, K.W.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A.; Agard, D.A.; Greene, G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol, 2002, 9, 359-64.
125. Kim, S.B.; Ozawa, T.; Watanabe, S.; Umezawa, Y. High-throughput sensing and noninvasive imaging of protein nuclear transport by using reconstitution of split Renilla luciferase. Proc. Natl. Acad. Sci USA, 2004, 101, 11542-7.
126. McDonnell, D.P.; Chang, C.Y.; Norris, J.D. Development of peptide antagonists that target estrogen receptor-cofactor interactions. J. Steroid Biochem. Mol. Biol., 2000, 74, 327-35.
127. Zhao, C.; Deng, W.; Gage, F.H. Mechanisms and functional implications of adult neurogenesis. Cell, 2008, 132, 645-60.
128. Wong, E.Y.; Herbert, J. The corticoid environment: a determining factor for neural progenitors' survival in the adult hippocampus. Eur. J. Neurosci., 2004, 20, 2491-98.
129. Wong, E.Y.; Herbert, J. Raised circulating corticosterone inhibits neuronal differentiation of progenitor cells in the adult hippocampus. Neuroscience, 2006, 137, 83-92.
130. Cameron, H.A.; Gould, E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience, 1994, 61, 203-09.
131. Cameron, H.A.; McEwen, B.S.; Gould, E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J. Neurosci., 1995, 15, 4687-92.
132. Cameron, H.A.; McKay, R.D. Restoring production of hippocampal neurons in old age. Nat. Neurosci., 1999, 2, 894-7.
133. Gould, E.; Cameron, H.A.; Daniels, D.C.; Woolley, C.S.; McEwen, B.S. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J. Neurosci., 1992, 12, 3642-50.
134. Mirescu, C.; Peters, J.D.; Gould, E. Early life experience alters response of adult neurogenesis to stress. Nat. Neurosci., 2004, 7, 841-46.
135. Tanapat, P.; Hastings, N.B.; Rydel, T.A.; Galea, L.A.; Gould, E. Exposure to fox odor inhibits cell proliferation in the hippocampus of adult rats via an adrenal hormone-dependent mechanism. J. Comp. Neurol., 2001, 437, 496-504.
136. Fuchs, E.; Gould, E. Mini-review: in vivo neurogenesis in the adult brain: regulation and functional implications. Eur. J. Neurosci., 2000, 12, 2211-14.
137. Gould, E.; Tanapat, P. Stress and hippocampal neurogenesis. Biol. Psychiatry, 1999, 46, 1472-79.
138. Gould, E.; Woolley, C.S.; McEwen, B.S. Adrenal steroids regulate postnatal development of the rat dentate gyrus: I. Effects of glucocorticoids on cell death. J. Comp. Neurol., 1991, 313, 479-85.
139. Karten, Y.J.; Stienstra, C.M.; Joels, M. Corticosteroid effects on serotonin responses in granule cells of the rat dentate gyrus. J. Neuroendocrinol., 2001, 13, 233-38.
140. Kim, J.B.; Ju, J.Y.; Kim, J.H.; Kim, T.Y.; Yang, B.H.; Lee, Y.S.; Son, H. Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro. Brain Res., 2004, 1027, 1-10.
141. McEwen, B.S. Effects of adverse experiences for brain structure and function. Biol. Psychiatry, 2000, 48, 721-31.
142. Leuner, B.; Mendolia-Loffredo, S.; Kozorovitskiy, Y.; Samburg, D.; Gould, E.; Shors, T.J. Learning enhances the survival of new neurons beyond the time when the hippocampus is required for memory. J. Neurosci., 2004, 24, 7477-81.
143. Benaroya-Milshtein, N.; Hollander, N.; Apter, A.; Kukulansky, T.; Raz, N.; Wilf, A.; Yaniv, I.; Pick, C.G. Environmental enrichment in mice decreases anxiety, attenuates stress responses and enhances natural killer cell activity. Eur. J. Neurosci., 2004, 20, 1341-7.
144. Moncek, F.; Duncko, R.; Johansson, B.B.; Jezova, D. Effect of environmental enrichment on stress related systems in rats. J. Neuroendocrinol., 2004, 16, 423-31.
145. Brown, J.; Cooper-Kuhn, C.M.; Kempermann, G.; van, P.H.; Winkler, J.; Gage, F.H.; Kuhn, H.G. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur. J. Neurosci., 2003, 17, 2042-46.
146. Droste, S.K.; Gesing, A.; Ulbricht, S.; Muller, M.B.; Linthorst, A.C.; Reul, J.M. Effects of long-term voluntary exercise on the mouse hypothalamic-pituitary-adrenocortical axis. Endocrinology, 2003, 144, 3012-23.
147. Fabel, K.; Tam, B.; Kaufer, D.; Baiker, A.; Simmons, N.; Kuo, C.J.; Palmer, T.D. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur. J. Neurosci., 2003, 18, 2803-12.
148. Farmer, J.; Zhao, X.; van, P.H.; Wodtke, K.; Gage, F.H.; Christie, B.R. Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley rats in vivo. Neuroscience, 2004, 124, 71-79.
149. van Praag, H.; Christie, B.R.; Sejnowski, T.J.; Gage, F.H. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl. Acad. Sci. USA, 1999, 96, 13427-31.
150. van Praag, H.; Kempermann, G.; Gage, F.H. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat. Neurosci., 1999, 2, 266-70.
151. Kempermann, G.; Kuhn, H.G.; Gage, F.H. More hippocampal neurons in adult mice living in an enriched environment. Nature, 1997, 386, 493-95.
152. Leuner, B.; Gould, E.; Shors, T.J. Is there a link between adult neurogenesis and learning? Hippocampus, 2006, 16, 216-24.
153. Mirescu, C.; Gould, E. Stress and adult neurogenesis. Hippocampus, 2006,
154. Nilsson, M.; Perfilieva, E.; Johansson, U.; Orwar, O.; Eriksson, P.S. Enriched environment increases neurogenesis in the adult rat dentate gyrus and improves spatial memory. J. Neurobiol., 1999, 39, 569-78.
155. Duman, R.S.; Malberg, J.; Nakagawa, S.; D'Sa, C. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry, 2000, 48, 732-39.
156. Jacobs, B.L.; Praag, H.; Gage, F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry, 2000, 5, 262-69.
157. Kempermann, G.; Gast, D.; Kronenberg, G.; Yamaguchi, M.; Gage, F.H. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development, 2003, 130, 391-9.
158. Malberg, J.E.; Schechter, L.E. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharm. Des., 2005, 11, 145-55.
159. McEwen, B.S. Mood disorders and allostatic load. Biol. Psychiatry, 2003, 54, 200-07.
160. McEwen, B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism, 2005, 54, 20-23.
161. Nemeroff, C.B.; Vale, W.W. The neurobiology of depression: inroads to treatment and new drug discovery. J. Clin. Psychiatry, 2005, 66(Suppl. 7), 5-13.
162. Sahay, A.; Hen, R. Adult hippocampal neurogenesis in depression. Nat. Neurosci., 2007, 10, 1110-15.
163. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 2003, 301, 805-9.
164. de Kloet, E.R.; Sibug, R.M.; Helmerhorst, F.M.; Schmidt, M.V. Stress, genes and the mechanism of programming the brain for later life. Neurosci. Biobehav. Rev., 2005, 29, 271-81.
165. Sahay, A.; Drew, M.R.; Hen, R. Dentate gyrus neurogenesis and depression. Prog. Brain Res., 2007, 163, 697-722.
166. Lawrence, J.J.; McBain, C.J. Interneuron diversity series: containing the detonation - feedforward inhibition in the CA3 hippocampus. Trends Neurosci., 2003, 26, 631-40.
167. Kempermann, G. Regulation of adult hippocampal neurogenesis - implications for novel theories of major depression. Bipolar. Disord., 2002, 4, 17-33.
168. Joels, M.; van, R.E. Mineralocorticoid and glucocorticoid receptor-mediated effects on serotonergic transmission in health and disease. Ann. N. Y. Acad. Sci., 2004, 1032, 301-03.
169. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci., 2000, 20, 9104-10.
170. Carlezon, W.A., Jr.; Duman, R.S.; Nestler, E.J. The many faces of CREB. Trends Neurosci., 2005, 28, 436-45.
171. Cryan, J.F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci., 2002, 23, 238-45.
172. Duman, R.S.; Monteggia, L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry, 2006, 59, 1116-27.
173. Pariante, C.M.; Pearce, B.D.; Pisell, T.L.; Owens, M.J.; Miller, A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol. Pharmacol., 1997, 52, 571-81.
174. D'Sa, C.; Duman, R.S. Antidepressants and neuroplasticity. Bipolar. Disord., 2002, 4, 183-94.
175. Encinas, J.M.; Vaahtokari, A.; Enikolopov, G. Fluoxetine targets early progenitor cells in the adult brain. Proc. Natl. Acad. Sci. USA, 2006, 103, 8233-38.
176. Madsen, T.M.; Treschow, A.; Bengzon, J.; Bolwig, T.G.; Lindvall, O.; Tingstrom, A. Increased neurogenesis in a model of electroconvulsive therapy. Biol. Psychiatry, 2000, 47, 1043-49.
177. Malatesta, P.; Hartfuss, E.; Gotz, M. Isolation of radial glial cells by fluorescent-activated cell sorting reveals a neuronal lineage. Development, 2000, 127, 5253-63.
178. Manev, H.; Uz, T.; Smalheiser, N.R.; Manev, R. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur. J. Pharmacol., 2001, 411, 67-70.
179. Nakagawa, S.; Kim, J.E.; Lee, R.; Chen, J.; Fujioka, T.; Malberg, J.; Tsuji, S.; Duman, R.S. Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus. J. Neurosci., 2002, 22, 9868-76.
180. Heuser, I.; Lammers, C.H. Stress and the brain. Neurobiol. Aging, 2003, 24(Suppl 1), S69-S76.
181. Holsboer, F.; Liebl, R.; Hofschuster, E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J. Affect. Disord., 1982, 4, 93-101.
182. Holsboer-Trachsler, E.; Stohler, R.; Hatzinger, M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res., 1991, 38, 163-71.
183. Wodarz, N.; Rupprecht, R.; Kornhuber, J.; Schmitz, B.; Wild, K.; Riederer, P. Cell-mediated immunity and its glucocorticoid-sensitivity after clinical recovery from severe major depressive disorder. J. Affect. Disord., 1992, 25, 31-38.
184. Brady, L.S.; Gold, P.W.; Herkenham, M.; Lynn, A.B.; Whitfield, H.J., Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res., 1992, 572, 117-25.
185. Brady, L.S.; Whitfield, H.J., Jr.; Fox, R.J.; Gold, P.W.; Herkenham, M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest., 1991, 87, 831-37.
186. Kitayama, I.; Janson, A.M.; Cintra, A.; Fuxe, K.; Agnati, L.F.; Ogren, S.O.; Harfstrand, A.; Eneroth, P.; Gustafsson, J.A. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. J. Neural Transm., 1988, 73, 191-203.
187. Reul, J.M.; Labeur, M.S.; Grigoriadis, D.E.; De Souza, E.B.; Holsboer, F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology, 1994, 60, 509-19.
188. Reul, J.M.; Stec, I.; Soder, M.; Holsboer, F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology, 1993, 133, 312-20.
189. Huang, G.J.; Herbert, J. Serotonin modulates the suppressive effects of corticosterone on proliferating progenitor cells in the dentate gyrus of the hippocampus in the adult rat. Neuropsychopharmacology, 2005, 30, 231-41.
190. Wong, M.L.; Licinio, J. Research and treatment approaches to depression. Nat. Rev. Neurosci., 2001, 2, 343-51.
191. Dranovsky, A.; Hen, R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol. Psychiatry, 2006, 59, 1136-43.
192. Warner-Schmidt, J.L.; Duman, R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus, 2006, 16, 239-49.
193. Alfonso, J.; Aguero, F.; Sanchez, D.O.; Flugge, G.; Fuchs, E.; Frasch, A.C.; Pollevick, G.D. Gene expression analysis in the hippocampal formation of tree shrews chronically treated with cortisol. J. Neurosci. Res., 2004, 78, 702-10.
194. Ibi, D.; Takuma, K.; Koike, H.; Mizoguchi, H.; Tsuritani, K.; Kuwahara, Y.; Kamei, H.; Nagai, T.; Yoneda, Y.; Nabeshima, T.; Yamada, K. Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J. Neurochem., 2008, 105(3), 921-32.
195. Yalcin, I.; Aksu, F.; Belzung, C. Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. Eur. J. Pharmacol., 2005, 514, 165-74.
196. Esposito, M.S.; Piatti, V.C.; Laplagne, D.A.; Morgenstern, N.A.; Ferrari, C.C.; Pitossi, F.J.; Schinder, A.F. Neuronal differentiation in the adult hippocampus recapitulates embryonic development. J. Neurosci., 2005, 25, 10074-86.
197. Airan, R.D.; Meltzer, L.A.; Roy, M.; Gong, Y.; Chen, H.; Deisseroth, K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science, 2007, 317, 819-23.
198. Jiang, W.; Zhang, Y.; Xiao, L.; Van, C.J.; Ji, S.P.; Bai, G.; Zhang, X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest., 2005, 115, 3104-16.
199. Meltzer, L.J.; Mindell, J.A. Impact of a child's chronic illness on maternal sleep and daytime functioning. Arch. Intern. Med., 2006, 166, 1749-55.
200. Jayatissa, M.N.; Bisgaard, C.; Tingstrom, A.; Papp, M.; Wiborg, O. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology, 2006, 31, 2395-404.
201. Vollmayr, B.; Simonis, C.; Weber, S.; Gass, P.; Henn, F. Reduced cell proliferation in the dentate gyrus is not correlated with the development of learned helplessness. Biol. Psychiatry, 2003, 54, 1035-40.
202. Czeh, B.; Michaelis, T.; Watanabe, T.; Frahm, J.; de Biurrun, G.; van Kampen, M.; Bartolomucci, A.; Fuchs, E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl. Acad. Sci. USA, 2001, 98, 12796-801.
203. Malberg, J.E.; Duman, R.S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology, 2003, 28, 1562-71.
204. Meshi, D.; Drew, M.R.; Saxe, M.; Ansorge, M.S.; David, D.; Santarelli, L.; Malapani, C.; Moore, H.; Hen, R. Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat. Neurosci., 2006, 9, 729-31.
205. Holick, K.A.; Lee, D.C.; Hen, R.; Dulawa, S.C. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology, 2008, 33, 406-17.
206. Huang, G.J.; Herbert, J. Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone. Biol. Psychiatry, 2006, 59, 619-24.
207. Pinnock, S.B.; Balendra, R.; Chan, M.; Hunt, L.T.; Turner-Stokes, T.; Herbert, J. Interactions between nitric oxide and corticosterone in the regulation of progenitor cell proliferation in the dentate gyrus of the adult rat. Neuropsychopharmacology, 2007, 32, 493-504.
208. Mayer, J.L.; Klumpers, L.; Maslam, S.; de Kloet, E.R.; Joels, M.; Lucassen, P.J. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J. Neuroendocrinol., 2006, 18, 629-31.
209. Oomen, C.A.; Mayer, J.L.; de Kloet, E.R.; Joels, M.; Lucassen, P.J. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress. Eur. J. Neurosci., 2007, 26, 3395-401.
210. Wong, E.Y.; Herbert, J. Roles of mineralocorticoid and glucocorticoid receptors in the regulation of progenitor proliferation in the adult hippocampus. Eur. J. Neurosci., 2005, 22, 785-92.
211. Alonso, R.; Griebel, G.; Pavone, G.; Stemmelin, J.; Le, F.G.; Soubrie, P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol. Psychiatry, 2004, 9, 278-86, 24.
212. Vreugdenhil, E.; Kolk, S.M.; Boekhoorn, K.; Fitzsimons, C.P.; Schaaf, M.; Schouten, T.; Sarabdjitsingh, A.; Sibug, R.; Lucassen, P.J. Doublecortin-like, a microtubule-associated protein expressed in radial glia, is crucial for neuronal precursor division and radial process stability. Eur. J. Neurosci., 2007, 25, 635-48.
213. Francis, F.; Koulakoff, A.; Boucher, D.; Chafey, P.; Schaar, B.; Vinet, M.C.; Friocourt, G.; McDonnell, N.; Reiner, O.; Kahn, A. et al. Doublecortin is a developmentally regulated, microtubuleassociated protein expressed in migrating and differentiating neurons. Neuron, 1999, 23, 247-56.
214. Gleeson, J.G.; Lin, P.T.; Flanagan, L.A.; Walsh, C.A. Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Neuron, 1999, 23, 257-71.
215. Shu, T.; Tseng, H.C.; Sapir, T.; Stern, P.; Zhou, Y.; Sanada, K.; Fischer, A.; Coquelle, F.M.; Reiner, O.; Tsai, L.H. Doublecortin-like kinase controls neurogenesis by regulating mitotic spindles and m phase progression. Neuron, 2006, 49, 25-39.
216. Alvarez-Buylla, A.; Garcia-Verdugo, J.M.; Tramontin, A.D. A unified hypothesis on the lineage of neural stem cells. Nat. Rev. Neurosci., 2001, 2, 287-93.
217. Anthony, T.E.; Klein, C.; Fishell, G.; Heintz, N. Radial glia serve as neuronal progenitors in all regions of the central nervous system. Neuron, 2004, 41, 881-90.
218. Gotz, M.; Hartfuss, E.; Malatesta, P. Radial glial cells as neuronal precursors: a new perspective on the correlation of morphology and lineage restriction in the developing cerebral cortex of mice. Brain Res. Bull., 2002, 57, 777-88.
219. Malatesta, P.; Hack, M.A.; Hartfuss, E.; Kettenmann, H.; Klinkert, W.; Kirchhoff, F.; Gotz, M. Neuronal or glial progeny: regional differences in radial glia fate. Neuron, 2003, 37, 751-64.
220. Noctor, S.C.; Flint, A.C.; Weissman, T.A.; Dammerman, R.S.; Kriegstein, A.R. Neurons derived from radial glial cells establish radial units in neocortex. Nature, 2001, 409, 714-20.
221. Boekhoorn, K.; Sarabdjitsingh, A.; Kommerie, H.; de Punder, K.; Schouten, T.; Lucassen, P.J.; Vreugdenhil, E. Doublecortin (DCX) and doublecortin-like (DCL) are differentially expressed in the early but not late stages of murine neocortical development. J. Comp. Neurol., 2008, 507, 1639-52.
222. Galigniana, M.D.; Harrell, J.M.; Housley, P.R.; Patterson, C.; Fisher, S.K.; Pratt, W.B. Retrograde transport of the glucocorticoid receptor in neurites requires dynamic assembly of complexes with the protein chaperone hsp90 and is linked to the CHIP component of the machinery for proteasomal degradation. Brain. Res. Mol. Brain Res., 2004, 123, 27-36.
223. Galigniana, M.D.; Harrell, J.M.; O'Hagen, H.M.; Ljungman, M.; Pratt, W.B. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J. Biol. Chem., 2004, 279, 22483-9.
224. Pratt, W.B.; Galigniana, M.D.; Harrell, J.M.; DeFranco, D.B. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal., 2004, 16, 857-72.
225. Pratt, W.B.; Galigniana, M.D.; Morishima, Y.; Murphy, P.J. Role of molecular chaperones in steroid receptor action. Essays Biochem., 2004, 40, 41-58.
226. Wochnik, G.M.; Ruegg, J.; Abel, G.A.; Schmidt, U.; Holsboer, F.; Rein, T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem., 2005, 280, 4609-16.
227. Friocourt, G.; Chafey, P.; Billuart, P.; Koulakoff, A.; Vinet, M.C.; Schaar, B.T.; McConnell, S.K.; Francis, F.; Chelly, J. Doublecortin interacts with mu subunits of clathrin adaptor complexes in the developing nervous system. Mol. Cell. Neurosci., 2001, 18, 307-19.
228. Moores, C.A.; Perderiset, M.; Francis, F.; Chelly, J.; Houdusse, A.; Milligan, R.A. Mechanism of microtubule stabilization by double-cortin. Mol. Cell, 2004, 14, 833-9.
229. Fitzsimons, C.P.; Ahmed, S.; Wittevrongel, C.F.; Schouten, T.G.; Dijkmans, T.F.; Scheenen, W.J.; Schaaf, M.J.; Ronald de Kloet, E.; Vreugdenhil, E. The microtubule-associated protein doublecortin-like regulates the transport of the glucocorticoid receptor in neuronal progenitor cells. Mol. Endocrinol., 2008, 22, 248-62.